Stephen Salloway

Blood biomarkers in Alzheimer’s disease: appropriate use recommendations

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

The potential of plasma biomarkers in dementia

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab